--- title: "CapsoVision | 8-K: FY2026 Q2 Revenue: USD 3.643 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295843885.md" datetime: "2026-08-13T20:39:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295843885.md) - [en](https://longbridge.com/en/news/295843885.md) - [zh-HK](https://longbridge.com/zh-HK/news/295843885.md) generator: "portal-rs" --- # CapsoVision | 8-K: FY2026 Q2 Revenue: USD 3.643 M Revenue: As of FY2026 Q2, the actual value is USD 3.643 M. EPS: As of FY2026 Q2, the actual value is USD -0.15, missing the estimate of USD -0.13. EBIT: As of FY2026 Q2, the actual value is USD -7.481 M. ### Second Quarter 2026 Financial Results #### Revenue CapsoVision, Inc. reported total revenue of $3.6 million for the second quarter of 2026, representing a 10% increase year-over-year compared to $3.3 million in the second quarter of 2025. This growth was primarily driven by a 13% increase in CapsoCam Plus capsules sold, partially offset by an approximately 3% decrease in the average selling price. #### Gross Profit and Margin Gross profit for the second quarter of 2026 was $1.9 million, an increase of $0.1 million or 3% compared to the second quarter of 2025. The gross margin for the period was 51%, down from 55% in the second quarter of 2025, attributed to pressure on selling prices and increased expenses from changes in U.S. government trade policies and tariffs. #### Operating Expenses Total operating expenses for the second quarter of 2026 were $9.5 million, an increase of $3.0 million from $6.462 million in the second quarter of 2025. This rise was mainly due to expenses associated with the colon pivotal study and other clinical trials, non-recurring engineering services for the Canon development project, costs of operating as a public company, and stock-based compensation. Selling and marketing expenses were $1,936 thousand in Q2 2026, up from $1,847 thousand in Q2 2025. Research and development expenses increased to $5,309 thousand in Q2 2026 from $3,392 thousand in Q2 2025. General and administrative expenses rose to $2,206 thousand in Q2 2026 from $1,223 thousand in Q2 2025. #### Operating Loss CapsoVision, Inc. reported an operating loss of - $7,580 thousand for the second quarter of 2026, compared to an operating loss of - $4,651 thousand in the second quarter of 2025. #### Non-Operating Income Total non-operating income, net, was $99 thousand in Q2 2026, up from $26 thousand in Q2 2025. This included net interest income of $82 thousand (compared to $37 thousand in Q2 2025) and other non-operating income (expense), net, of $17 thousand (compared to - $11 thousand in Q2 2025). #### Net Loss Net loss and comprehensive loss for the second quarter of 2026 was - $7,481 thousand, compared to - $4,625 thousand in the second quarter of 2025. ### Six Months Ended June 30, 2026 Financial Results #### Revenue Net revenue for the six months ended June 30, 2026, was $6,435 thousand, compared to $6,098 thousand for the same period in 2025. #### Gross Profit Gross profit for the six months ended June 30, 2026, was $3,200 thousand, a decrease from $3,305 thousand in the prior year period. #### Operating Expenses Total operating expenses for the six months ended June 30, 2026, were $17,873 thousand, up from $13,338 thousand for the same period in 2025. Selling and marketing expenses were $4,027 thousand in 2026 vs. $3,808 thousand in 2025. Research and development expenses were $9,744 thousand in 2026 vs. $6,499 thousand in 2025. General and administrative expenses were $4,102 thousand in 2026 vs. $3,031 thousand in 2025. #### Operating Loss Operating loss for the six months ended June 30, 2026, was - $14,673 thousand, compared to - $10,033 thousand for the same period in 2025. #### Net Loss Net loss and comprehensive loss for the six months ended June 30, 2026, was - $14,514 thousand, compared to - $10,000 thousand for the same period in 2025. ### Balance Sheet Highlights (as of June 30, 2026) #### Cash and Cash Equivalents Cash and cash equivalents totaled $9,077 thousand as of June 30, 2026, down from $10,112 thousand as of December 31, 2025. #### Total Assets Total assets were $18,569 thousand as of June 30, 2026, compared to $18,164 thousand as of December 31, 2025. #### Total Liabilities Total liabilities were $5,403 thousand as of June 30, 2026, compared to $4,904 thousand as of December 31, 2025. ### Cash Flow Highlights (Six Months Ended June 30, 2026) #### Net Cash Used in Operating Activities Net cash used in operating activities was - $14,469 thousand for the six months ended June 30, 2026, compared to - $9,512 thousand for the same period in 2025. #### Net Cash Used in Investing Activities Net cash used in investing activities was - $48 thousand for the six months ended June 30, 2026, compared to - $70 thousand for the same period in 2025. #### Net Cash Provided by Financing Activities Net cash provided by financing activities was $13,509 thousand for the six months ended June 30, 2026, significantly up from $1,202 thousand for the same period in 2025, primarily due to $14,000 thousand in proceeds from a Private Placement. #### Net Decrease in Cash and Cash Equivalents The net decrease in cash and cash equivalents was - $1,008 thousand for the six months ended June 30, 2026, compared to a decrease of - $8,380 thousand for the same period in 2025. ### Operational Metrics As of June 30, 2026, CapsoCam Plus® has been used by over 176,000 patients. ### Unique Financial Indicators CapsoVision, Inc. entered into a sales agreement for an at-the-market equity offering program of up to $100 million with Cantor. The company may issue and sell shares of common stock with an aggregate offering price of up to $100,000,000 through the Agent, paying the Agent a commission of up to 3.0% of the aggregate gross proceeds from each sale of Placement Shares. ### Outlook and Guidance CapsoVision, Inc. anticipates FDA clearance of AI Highlights™ by the end of the third quarter of 2026, with a U.S. commercial launch expected shortly thereafter. The company’s pipeline continues to advance, with CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026. Additionally, ongoing enrollment continues for the CapsoCam UGI clinical study for pancreatic cancer detection. ### Related Stocks - [CV.US](https://longbridge.com/en/quote/CV.US.md) ## Related News & Research - [CapsoVision Launches $100 Million At-The-Market Offering](https://longbridge.com/en/news/296215951.md) - [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md) - [Syn updates 2026 financial calendar for interim results release](https://longbridge.com/en/news/296331010.md) - [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**